Open access
104
Views
3
CrossRef citations to date
0
Altmetric
Original Research
EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation
Konstanze Diefenbach1 Bayer HealthCare Pharmaceuticals, Berlin, Germany
, Dietmar Trummer1 Bayer HealthCare Pharmaceuticals, Berlin, Germany
, Frank Ebert1 Bayer HealthCare Pharmaceuticals, Berlin, Germany
, Michael Lissy2 Nuvisan GmbH, Neu-Ulm, Germany
, Manuela Koch2 Nuvisan GmbH, Neu-Ulm, Germany
, Beate Rohde1 Bayer HealthCare Pharmaceuticals, Berlin, Germany
& Hartmut Blode3 Bayer HealthCare Pharmaceuticals Global R&D Center, Beijing, People’s Republic of ChinaCorrespondence[email protected]
show all
Pages 149-163
|
Published online: 11 Apr 2013
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.